Global Anti-Obesity Prescription Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Anti-Obesity Prescription Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
Anti-Obesity Prescription Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anti-Obesity Prescription Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anti-Obesity Prescription Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Anti-Obesity Prescription Drugs key manufacturers include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim and Alizyme, etc. F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s are top 3 players and held % sales share in total in 2022.
Anti-Obesity Prescription Drugs can be divided into Pediatric and Adult, etc. Pediatric is the mainstream product in the market, accounting for % sales share globally in 2022.
Anti-Obesity Prescription Drugs is widely used in various fields, such as Hospitals Pharmacies, Retail Pharmacies and E-commerce,, etc. Hospitals Pharmacies provides greatest supports to the Anti-Obesity Prescription Drugs industry development. In 2022, global % sales of Anti-Obesity Prescription Drugs went into Hospitals Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-Obesity Prescription Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Segment by Type
Pediatric
Adult
Hospitals Pharmacies
Retail Pharmacies
E-commerce
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Anti-Obesity Prescription Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-Obesity Prescription Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-Obesity Prescription Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-Obesity Prescription Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-Obesity Prescription Drugs introduction, etc. Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Anti-Obesity Prescription Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Anti-Obesity Prescription Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Anti-Obesity Prescription Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals Pharmacies and Retail Pharmacies are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Anti-Obesity Prescription Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Anti-Obesity Prescription Drugs key manufacturers include F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s, Arena Pharmaceuticals, Glaxosmithkline, Vivus, Boehringer Ingelheim and Alizyme, etc. F Hoffmann La Roche Ltd, Orexigen Therapeutics, Novo Nordisk A/s are top 3 players and held % sales share in total in 2022.
Anti-Obesity Prescription Drugs can be divided into Pediatric and Adult, etc. Pediatric is the mainstream product in the market, accounting for % sales share globally in 2022.
Anti-Obesity Prescription Drugs is widely used in various fields, such as Hospitals Pharmacies, Retail Pharmacies and E-commerce,, etc. Hospitals Pharmacies provides greatest supports to the Anti-Obesity Prescription Drugs industry development. In 2022, global % sales of Anti-Obesity Prescription Drugs went into Hospitals Pharmacies filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Anti-Obesity Prescription Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
F Hoffmann La Roche Ltd
Orexigen Therapeutics
Novo Nordisk A/s
Arena Pharmaceuticals
Glaxosmithkline
Vivus
Boehringer Ingelheim
Alizyme
Segment by Type
Pediatric
Adult
Segment by Application
Hospitals Pharmacies
Retail Pharmacies
E-commerce
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Anti-Obesity Prescription Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Anti-Obesity Prescription Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Anti-Obesity Prescription Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Anti-Obesity Prescription Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Anti-Obesity Prescription Drugs introduction, etc. Anti-Obesity Prescription Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Anti-Obesity Prescription Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices